Sign In
Buy ABUS
$4.35
+0.0900 (+2.11%)
At Close: Jun 03, 2026
Why Arbutus (ABUS) Stock Might be a Great Pick
03:04pm, Friday, 15'th May 2020
Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Arbutus' Shares March Higher, Can It Continue?
01:15pm, Friday, 15'th May 2020
As of late, it has definitely been a great time to be an investor in Arbutus Biopharma.
3 “Strong Buy” Penny Stocks With Triple-Digit Upside
06:22pm, Thursday, 14'th May 2020
Given the troubling state of the U.S. economy, what’s driving the bullish sentiment on Wall Street? Stimulus.Among the bulls is chief investment strategist at CFRA, Sam Stovall, who estimates that t
Arbutus to Present at UBS Virtual Global Healthcare Conference
12:00pm, Tuesday, 12'th May 2020
WARMINSTER, Pa., May 12, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.
Moving Average Crossover Alert: Arbutus Biopharma
03:19pm, Monday, 11'th May 2020
Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
11:45am, Monday, 11'th May 2020
Arbutus (ABUS) delivered earnings and revenue surprises of 21.88% and -17.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma: Q1 Earnings Insights
11:12am, Monday, 11'th May 2020
Shares of Arbutus Biopharma (NASDAQ:ABUS) rose 12.6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 46.81% year over year to ($0.25), which beat
Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challenges Conference Call and Webcast Scheduled Today at 8:00 AM ET WARMINSTER, Pa., May 11,.
Arbutus to Report First Quarter 2020 Financial Results
12:00pm, Monday, 04'th May 2020
WARMINSTER, Pa., May 04, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled.
The Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Have Been Trimming Their Sales Forecasts
10:16am, Tuesday, 31'st Mar 2020
One thing we could say about the analysts on Arbutus Biopharma Corporation (NASDAQ:ABUS) - they aren't optimistic...
ABT, DD among premarket gainers
01:22pm, Monday, 30'th Mar 2020
Plus Therapeutics. (NASDAQ:PSTV) +63% in-licenses novel oncology candidates.Bellerophon Therapeutics (NASDAQ:BLPH) +40% as first COVID-19 patient has been treated with the INOpulse inhaled nitric o
CCL, RBS among premarket losers
01:22pm, Friday, 27'th Mar 2020
Arlington Asset Investment (NYSE:AI) -21% after suspending Q1 dividend.BGC Partners (NASDAQ:BGCP) -20% on dividend cut.Altimmune (NASDAQ:ALT) -15% on FY earnings.Arbutus Biopharma (NASDAQ:ABUS)�
B.Riley FBR Keeps Their Buy Rating on Arbutus Biopharma (ABUS)
12:16pm, Friday, 27'th Mar 2020
B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arbutus Biopharma (ABUS) today and set a price target of $6.00. The company's shares closed
B.Riley FBR Keeps Their Buy Rating on Arbutus Biopharma (ABUS)
12:16pm, Friday, 27'th Mar 2020
B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Arbutus Biopharma (ABUS – Research Report) today and set a
The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance
12:02pm, Friday, 27'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.None of the NYSE- or Nasdaq-listed biotech stocks hit 52 week highs Thursday.Down In The Dumps (Biotech Stocks Hitting
